ライフサイエンスコーパス: 18F-fluorodeoxyglucose

1 rcinoma were correctly detected by PET using 18F-fluorodeoxyglucose.

2 opsychological testing, and PET imaging with 18F-fluorodeoxyglucose.

3 cerebral glucose metabolism determined with 18F-fluorodeoxyglucose.

4 ain were reported previously using PET with [18F]fluorodeoxyglucose.

5 ers with positron emission tomography using [18F]fluorodeoxyglucose.

6 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tom

7 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel bio

8 uptake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active pl

9 e show that PET imaging with 11C-acetate and 18F-fluorodeoxyglucose (18F-FDG) functionally visualizes

10 odiscitis, and fever of unknown origin, when 18F-fluorodeoxyglucose (18F-FDG) is not available.

11 Conversely, 18F-fluorodeoxyglucose (18F-FDG) PET signal was not diff

12 orectal cancer (CRC) underwent 68Ga-FAPI and 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging.

13 The guidelines support the use of 2-18F-fluorodeoxyglucose (18F-FDG) positron emission tomog

14 ssessed by 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of

15 marker of cholinergic terminal density, and 18F-fluorodeoxyglucose (18F-FDG) was performed in a coho

16 Metabolic imaging with 18F-fluorodeoxyglucose ([18F]FDG) occurred 28 and 58 day

17 Whole-body 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomo

18 We performed dynamic [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomo

19 s examined by magnetic resonance (MR) or by [18F]fluorodeoxyglucose ([18F]FDG) uptake by positron emi

20 C]MeNTI and [11C]carfentanil ([11C]CFN) and [18F]fluorodeoxyglucose ([18F]FDG), respectively.

21 Recent studies using PET with 18F-fluorodeoxyglucose (18FDG) have shown the presence o

22 re myocardial blood flow in combination with 18F-fluorodeoxyglucose (18FDG) to assess myocardial viab

23 w prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomogra

24 The glucose analogue [18F]-fluorodeoxyglucose (18FDG) can be used to image inf

25 aging of positron-emitting tracers, such as [18F]fluorodeoxyglucose (18FDG), possible.

26 educed glucose metabolism, identified using [18F]fluorodeoxyglucose (18FDG), that is commonly more ex

27 used leukocyte uptake of the glucose analog [18F]fluorodeoxyglucose (18FDG), which indicates postmigr

28 Positron emission tomographic imaging with [18F]fluorodeoxyglucose ([18FDG]) could be used as a noni

29 y tracer used for assessment of viability is 18F-fluorodeoxyglucose, a glucose analogue that exhibits

30 sitron emission tomography imaging utilizing 18F-fluorodeoxyglucose and perfusion tracers provides va

31 structural and diffusion tensor imaging MRI, 18F-fluorodeoxyglucose and Pittsburgh compound B PET.

32 raphy (PET) to measure CBF (N = 19) or with [18F] fluorodeoxyglucose and PET to measure cerebral gluc

33 Positron emission tomography with [18F]fluorodeoxyglucose and matching MRI scans were obtai

34 We have used [18F]fluorodeoxyglucose and PET to identify specific meta

35 Imaging with [18F]fluorodeoxyglucose and positron emission tomography

36 DYT1 carriers and 14 normal volunteers with [18F]fluorodeoxyglucose and positron emission tomography.

37 erformed positron emission tomography using [18F]fluorodeoxyglucose and structural magnetic resonance

38 ex (measuring brain glucose metabolism with [18F]fluorodeoxyglucose) and dopamine increases (measured

39 erence between bSUVmax of the most and least 18F-fluorodeoxyglucose-avid lymphoma sites) was 8.0 (ran

40 -CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practi

41 d flow (with [15O]H2O) and metabolism (with [18F]fluorodeoxyglucose) before the start of therapy and

42 ffer between age groups.18F-flortaucipir and 18F-fluorodeoxyglucose, but not 11C-Pittsburgh compound

43 (positron emission computed tomography with 18F-fluorodeoxyglucose, cardiac computed tomography), an

44 ed agents: metabolism can be identified with 18F fluorodeoxyglucose (FDG), receptor expression with 9

45 We also measured glucose uptake using 18F- fluorodeoxyglucose (FDG)-positron emission tomograp

46 effect of insulin on myocardial kinetics of 18F-fluorodeoxyglucose (FDG) and glucose in patients wit

47 nd Yahr stage 3.8 +/- 1.0) with quantitative 18F-fluorodeoxyglucose (FDG) and positron emission tomog

48 body PET on a patient and lesion basis using 18F-fluorodeoxyglucose (FDG) for the detection of tumor

49 Whole-body PET imaging with 18F-fluorodeoxyglucose (FDG) has been shown to be effect

50 a case of Castleman's disease demonstrating 18F-fluorodeoxyglucose (FDG) localization by whole-body

51 stained a mild traumatic brain injury had an 18F-fluorodeoxyglucose (FDG) PET brain study using coinc

52 imize the semiquantitative interpretation of 18F-fluorodeoxyglucose (FDG) PET scans in the diagnosis

53 e knottin peptide are compared with standard 18F-fluorodeoxyglucose (FDG) PET small animal imaging.

54 xically display elevated HPC glucose uptake [18F-fluorodeoxyglucose (FDG) PET standardized uptake val

55 ssociated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomograph

56 metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomograph

57 Radionuclide imaging with 18F-fluorodeoxyglucose (FDG) positron emission tomograph

58 ore the impact of adjunctive rosuvastatin on 18F-fluorodeoxyglucose (FDG) positron emission tomograph

59 rience with coincidence detection imaging of 18F-fluorodeoxyglucose (FDG) using a dual-head gamma cam

60 PET, using the radiotracer 18F-fluorodeoxyglucose (FDG), permits the measurement of

61 fine the total body distribution kinetics of 18F-fluorodeoxyglucose (FDG), to contribute to its radia

62 arietal pattern of glucose hypometabolism on 18F-fluorodeoxyglucose (FDG)-PET imaging, previous studi

63 terior cortical hypometabolism measured with 18F-fluorodeoxyglucose (FDG)-PET is a well-known marker

64 reperfusion with PET and the glucose analog 18F-fluorodeoxyglucose (FDG).

65 by positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG).

66 mb perfusion and underwent PET scanning with 18F-fluorodeoxyglucose (FDG).

67 f tumor energetics, obtained by imaging with 18F-fluorodeoxyglucose (FDG).

68 sion tomography with metabolic tracers like [18F]-fluorodeoxyglucose (FDG) also appears to offer new

69 orcine myocardial stunning on the uptake of [18F]-fluorodeoxyglucose (FDG) at 24 hr and 7 days after

70 At each timepoint they were scanned with [18F]-fluorodeoxyglucose (FDG) to assess longitudinal cha

71 MRI) and positron emission tomography using [18F]-fluorodeoxyglucose (FDG-PET) were acquired on a hyb

72 Using dynamic [18F]fluorodeoxyglucose (FDG) and PET, kinetic rate const

73 regions of the conscious rodent brain using [18F]fluorodeoxyglucose (FDG) as the tracer, and to monit

74 Quantitative [18F]fluorodeoxyglucose (FDG) PET has considerable potent

75 The reliability of serial [18F]fluorodeoxyglucose (FDG) PET scans for psychopharmac

76 In a previous [18F]fluorodeoxyglucose (FDG) PET study we analyzed regio

77 Dynamic [18F]fluorodeoxyglucose (FDG) PET was used in Parkinson's

78 A whole-body [18F]fluorodeoxyglucose (FDG) positron emission tomograph

79 nd the antimicrobial response in VGEI using [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomograph

80 treatment correlate with tumor responses by [18F]fluorodeoxyglucose (FDG) positron emission tomograph

81 [18F]fluorodeoxyglucose (FDG) positron emission tomograph

82 Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomograph

83 ology and behavioral imaging with muPET and [18F]fluorodeoxyglucose (FDG) to generate whole-brain met

84 -handed men underwent scanning with PET and [18F]fluorodeoxyglucose (FDG) twice: before placebo and b

85 ested with positron emission tomography and [18F]fluorodeoxyglucose (FDG) under resting conditions; e

86 Positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) were used to measure region

87 We have used [18F]fluorodeoxyglucose (FDG) with PET to identify region

88 nstance, the radiolabeled glucose analogue, [18F]fluorodeoxyglucose (FDG), is routinely used in posit

89 -handed men were scanned twice with PET and [18F]fluorodeoxyglucose (FDG): before placebo and before

90 However, a whole-body PET scan with [18F]fluorodeoxyglucose (FDG-PET) was negative in these r

91 egistered positron emission tomography with [18F]fluorodeoxyglucose for metabolic assessment and core

92 ikingly, A+S+ patients had parieto-occipital 18F-fluorodeoxyglucose hypometabolism (a measure of N) d

93 oral and lateral frontal cortex; more severe 18F-fluorodeoxyglucose hypometabolism in the precuneus a

94 tients had posterior mismatch with excessive 18F-fluorodeoxyglucose hypometabolism relative to atroph

95 rogen-13 ammonia imaging, and metabolism by [18F]-fluorodeoxyglucose imaging.

96 of positron emission tomography (PET) with [18F]fluorodeoxyglucose in eight younger (mean age = 35 y

97 sured with positron emission tomography and [18F]fluorodeoxyglucose in five methamphetamine abusers w

98 Although functional imaging with 18F-fluorodeoxyglucose-labeled positron emission tomogra

99 18F-fluorodeoxyglucose mediated the relationship between

100 tion analyses estimated direct and indirect (18F-fluorodeoxyglucose mediated) local associations betw

101 ositron emission tomographic measurement of [18F]fluorodeoxyglucose myocardial distribution also was

102 eshold for defining brain boundaries in both 18F-fluorodeoxyglucose (n = 8) and 15O-water (n = 12) PE

103 18F-fluorodeoxyglucose PET (brain glucose metabolism PET

104 he brain, using quantitative MR-relaxometry, 18F-Fluorodeoxyglucose PET and immunohistochemistry in a

105 We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD wh

106 hypometabolism typically seen on interictal 18F-fluorodeoxyglucose PET imaging in patients with foca

107 bination of functional (high density EEG and 18F-fluorodeoxyglucose PET imaging) and structural (diff

108 r the study because of the prominent role of 18F-fluorodeoxyglucose PET in the staging of lung cancer

109 18F-fluorodeoxyglucose PET-CT may guide treatment decisi

110 ed longitudinally with [11C]-raclopride and [18F]-fluorodeoxyglucose PET imaging, with scans at basel

111 fest HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metaboli

112 atterns of atrophy on MRI, hypometabolism on 18F-fluorodeoxyglucose-PET and tau uptake on flortaucipi

113 18F-fluorodeoxyglucose-PET can reliably guide selective

114 Neuroimaging with MRI and 18F-fluorodeoxyglucose-PET revealed widespread bilateral

115 n, [18F]FLT-PET was found to be superior to [18F]fluorodeoxyglucose-PET (NUV60 versus LIPCNA: r = 0.8

116 ting cerebral metabolism was measured using [18F]fluorodeoxyglucose-PET and analysed with the techniq

117 Each subject underwent [18F]fluorodeoxyglucose-PET and neuropsychological testin

118 halamic lesions with metabolic imaging using 18F- fluorodeoxyglucose positron emission tomography-com

119 To investigate the diagnostic yield of 18F-fluorodeoxyglucose positron emission tomography (18F

120 18F-fluorodeoxyglucose positron emission tomography (18F

121 The introduction of 18F-fluorodeoxyglucose positron emission tomography (18F

122 Although 18F-fluorodeoxyglucose positron emission tomography (FDG

123 variables, atrophy on MRI, hypometabolism on 18F-fluorodeoxyglucose positron emission tomography (FDG

124 nt of response after radiotherapy (RT) using 18F-fluorodeoxyglucose positron emission tomography (PET

125 uantification software application to hybrid 18F-fluorodeoxyglucose positron emission tomography (PET

126 and the impact of an end-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET

127 Cerebral 18F-fluorodeoxyglucose positron emission tomography in 1

128 In 4 DSP cases with 18F-fluorodeoxyglucose positron emission tomography scan

129 derwent a combination of laboratory testing, 18F-fluorodeoxyglucose positron emission tomography scan

130 We use 18F-fluorodeoxyglucose positron emission tomography to i

131 18F-fluorodeoxyglucose positron emission tomography was

132 ential benefit of prompt diagnosis, aided by 18F-fluorodeoxyglucose positron emission tomography, and

133 independent predictor of thyroid malignancy; 18F-fluorodeoxyglucose positron emission tomography, whi

134 18F-fluorodeoxyglucose positron emission tomography-comp

135 rial and LN inflammation were measured using 18F-fluorodeoxyglucose positron emission tomography.

136 18F-fluorodeoxyglucose positron emission tomography/comp

137 150-minute personalized cooling protocol and 18F-fluorodeoxyglucose positron emission tomography/comp

138 erence, this study evaluated the accuracy of 18F-fluorodeoxyglucose positron emission tomography/comp

139 We report two cases of SOS investigated by 18F-fluorodeoxyglucose positron emission tomography/comp

140 hout PTSD, and 22 healthy controls underwent 18F-fluorodeoxyglucose positron emission tomography/magn

141 Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magn

142 ethylation status, and metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

143 Response to treatment was evaluated using [18F] fluorodeoxyglucose positron emission tomography (PE

144 with Staphylococcus aureus bacteremia (SAB) [18F] fluorodeoxyglucose positron emission tomography/com

145 gnal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PE

146 Magnetic resonance and [18F]-fluorodeoxyglucose positron emission tomography bra

147 tients were scanned with both [15O]-H2O and [18F]-fluorodeoxyglucose positron emission tomography in

148 and Alzheimer's disease (AD) patients with [18F]-fluorodeoxyglucose positron emission tomography usi

149 To study whether changes of [18F]fluorodeoxyglucose positron emission tomography (FDG

150 t ventricular function by echocardiography, [18F]fluorodeoxyglucose positron emission tomography of m

151 The subjects underwent two [18F]fluorodeoxyglucose positron emission tomography scan

152 es of mood and cerebral glucose metabolism ([18F]fluorodeoxyglucose positron emission tomography) dur

153 able Alzheimer's disease is possible, using [18F]fluorodeoxyglucose positron emission tomography.

154 um standardized uptake value on pretreatment 18F-fluorodeoxyglucose-positron emission tomography corr

155 Based on clinical profile, 18F-fluorodeoxyglucose-positron emission tomography imag

156 18F-fluorodeoxyglucose-positron emission tomography scan

157 ast spin echo images of the temporal lobes; [18F]fluorodeoxyglucose-positron emission tomographic sca

158 tified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET

159 kin lesions confirmed the same disease, and [18F]fluorodeoxyglucose-positron emission tomography demo

160 In recent years metabolic imaging with [18F]fluorodeoxyglucose-positron emission tomography has

161 ver ultrasounds, computed tomography scans, [18F]fluorodeoxyglucose-positron emission tomography scan

162 res (structural magnetic resonance imaging, [18F]fluorodeoxyglucose-positron emission tomography, per

163 ssion tomography techniques: [15O]water and [18F]fluorodeoxyglucose, respectively.

164 Positron emission tomography with [18F]fluorodeoxyglucose revealed widespread hypometabolis

165 n (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeoxyglucose scanning.

166 omography with sestamibi or tetrofosmin, and 18F-fluorodeoxyglucose single-photon emission computed t

167 twice with positron emission tomography and [18F]fluorodeoxyglucose; the first scan was obtained afte

168 ilability of dopamine D2 receptors and with [18F]fluorodeoxyglucose to assess regional brain glucose

169 phy was used with [11C]flumazenil (FMZ) and [18F]fluorodeoxyglucose to study GABA type A/benzodiazepi

170 Positron emission tomography with an [18F]fluorodeoxyglucose tracer was used in a within-subje

171 The finding of enhanced 18F-fluorodeoxyglucose uptake and a relative reduction i

172 , we found that the changes in [18F]FLT and [18F]fluorodeoxyglucose uptake were due to changes in lev

173 Positron emission tomography (PET) with [18F]fluorodeoxyglucose was used to determine cerebral me

174 Positron emission tomography with [18F]fluorodeoxyglucose was used to determine cerebral me